Fig. 3: Development of PPARγ immunohistochemical assay to enrich likelihood of response to FX-909.

a, PPARγ mRNA expression stratified by lineage (luminal, N = 21; nonluminal N = 5 patients). Box plots display the median and interquartile range; whiskers denote the 5th to 95th percentile range. Two-sided Wilcoxon rank-sum test was used for statistical analysis. b, Nuclear tumor staining of PPARγ by IHC, showing PPARγ-high (100% TPS), PPARγ-expressing (50% TPS) and PPARγ-absent (0% TPS) patterns. Scale bar, 200 μm. For each patient, a hematoxylin and eosin (H&E) stain was performed to assess tissue morphology, and a negative control was included in the same experimental procedure. c, Waterfall plot of the best percentage change in SLD from baseline in patients with advanced UC with PPARγ-high tumors (N = 25; Supplementary Fig. 6a). d, Swimmer plot showing radiographic response over time in PPARγ-high subgroup. Note that, at the time of the data cut, dosing logs were incomplete for some of the patients and the swim lane plots were only plotted over the time that the dosing information was available. e, Spider plot of the percentage change in SLD from baseline over time in the PPARγ-high subgroup. f, Waterfall plot depicting molecular response as percentage change from baseline in ctDNA aVAF at the cycle 2 or 3 time point. Patients with undetectable ctDNA at baseline were excluded (N = 25; Supplementary Table 7). EOT, end of treatment.